The Team at Seroba Kernel

Jonathan Hepple

Jonathan Hepple is a Partner of Seroba Kernel Life Sciences Limited and also a Partner of Rosetta Capital Limited (London).  Jonathan is based in Oxford and has been working with Seroba since 2003.  He currently sits on the board of Covagen AG (Switzerland).
 
Jonathan was a co-founder in 2001 of BioScience Managers Ltd (BML), a London-based advisory and private equity firm focused on the life sector.  At BML, Jonathan was responsible for the origination and execution of numerous corporate advisory transactions for biotechnology and medical device companies.  Since 2006, BML (re-named Rosetta Capital Ltd) has focused on acquiring portfolios of healthcare investments through secondary transactions.  At Rosetta, Jonathan manages portfolio investments in Tranzyme (USA), GeminX (acquired by Cephalon in 2011) and Zealand Pharma (Denmark).
 
Prior to founding BML, Jonathan was a member of the healthcare investment team at Rothschilds and was responsible for the management of Biotechnology Investments Limited (“BIL”) and the International Biotechnology Trust (“IBT”).  During his tenure at Rothschilds from 1998 until 2001, the BIL NAV grew to $600 million and IBT’s NAV grew to over £350 million. Prior to his PhD, Jonathan spent a year conducting research at British Biotechnology plc.
 
Jonathan received a PhD from Cambridge University for cancer research in 1997 and a BA from Oxford University in 1992.